Esophageal Cancer (ESCR)
Esophageal cancer (ESCR) poses significant challenges due to its dismal prognosis and limited therapy alternatives. This malignancy is characterized by the uncontrolled growth of cells within the esophagus, the tube connecting the throat and stomach. Leveraging our extensive expertise and cutting-edge technology, our company is committed to offering comprehensive services for the development of drugs and therapies targeting ESCR.
Introduction to Esophageal Cancer (ESCR)
Esophageal cancer (ESCR) is a malignant tumor originating in the esophagus. The incidence of ESCR ranges from 1 to 9 cases per 100,000 population. This cancer exhibits high aggressiveness, with a propensity for rapid dissemination to nearby lymph nodes and distant organs. ESCR is categorized into two main subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC is more prevalent in specific regions, such as Asia and Africa, while EAC is commonly found in Western countries.
Alternative names:
- Aerodigestive tract cancer
- Esophageal squamous cell carcinoma
- Gastric cardia adenocarcinoma
Pathogenesis of Esophageal Cancer (ESCR)
The development of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) involves a complex interplay of genetic, environmental, and lifestyle factors. EAC is primarily linked to chronic inflammation of the esophagus, often caused by gastroesophageal reflux disease (GERD). Conversely, ESCC is strongly associated with tobacco and alcohol use, as well as dietary factors. These two subtypes exhibit distinct molecular profiles and patterns of mutations, which contribute to their pathogenesis and offer potential targets for therapeutic interventions.
Fig.1 The risk factors profiles for esophageal adenocarcinoma. (Yang, Jianjun, et al., 2020)Targets of ESCR Therapy Development
The identification of specific targets for therapy is crucial in developing effective therapies for ESCR. Several key targets have been identified, including：
- Epidermal growth factor receptor (EGFR)
- Human epidermal growth factor receptor 2 (HER2)
- Vascular endothelial growth factor (VEGF)
- Programmed cell death protein 1 (PD-1)
- Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
Therapy Development of ESCR
| Surgery | ||
|---|---|---|
| Endoscopic resection | Esophagestomy combined with lymphadenectomy | |
| Radiation and chemotherapy | ||
| Neoadjuvant chemotherapy | Neoadjuvant chemoradiotherapy | |
| Chemotherapy | Radiotherapy | Chemoradiotherapy |
| Targeted therapy | ||
| Anti-EGFR therapy | Anti-PI3K/mTOR therapy | |
| Immunotherapy | ||
| Anti-PD-1 therapy | Anti-PD-L1 therapy | Anti-CTLA-4 therapy |
Our Services
Our company is at the forefront of esophageal cancer (ESCR) therapy development services. We have a dedicated team of highly skilled scientists and researchers who are committed to advancing the field of ESCR therapeutics. Our services include diagnostics development and the development of diverse therapies.
Therapy Development Platforms
Animal Models of Esophageal Cancer (ESCR)
Moreover, we specialize in the development of animal models that accurately mimic the characteristics of ESCR. These models play a crucial role in preclinical testing and provide valuable insights into the efficacy and safety of potential therapies. Our state-of-the-art equipment and expertise enable us to provide one-stop preclinical research services for ESCR studies, including drug safety evaluation as well as pharmacokinetic analysis.
| Chemical Induction Models | |||
|---|---|---|---|
| Our researchers have successfully developed rat models using the reflux model and NMBA induction methods. The reflux model involves surgically creating gastroesophageal reflux, a condition commonly associated with esophageal adenocarcinoma in humans. By inducing reflux in rats and subsequently exposing them to NMBA, we can accurately replicate the carcinogenesis process. | |||
| Optional Models |
|
|
|
| Xenograft Models | |||
| Xenograft models have revolutionized cancer research by enabling the transplantation of human tumor cells into immunodeficient mice, allowing for the evaluation of tumor growth, metastasis, and therapeutic efficacy. Our company offers state-of-the-art xenograft model development services, tailored to study esophageal squamous cell carcinoma (ESCC) and other subtypes of esophageal cancer. | |||
| Optional Models |
|
|
|
| Transgenic Models | |||
| Transgenic models have become indispensable tools in cancer research, allowing for the study of specific genetic alterations implicated in tumor initiation and progression. By overexpressing or knocking out key genes such as p53, PTEN, or EGFR, we can mimic the molecular alterations observed in human esophageal cancer. | |||
| Optional Species | Mouse (Mus musculus), Rabbit (Oryctolagus cuniculus), Guinea pig (Cavia porcellus), Hamster (Mesocricetus auratus), Others | ||
In addition to chemical induction models, xenograft models, and transgenic models, our company offers a range of other innovative model development services to cater to diverse research needs in the field of esophageal cancer. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Yang, Jianjun, et al. "Understanding esophageal cancer: the challenges and opportunities for the next decade." Frontiers in oncology 10 (2020): 1727.
- Sheikh, Mahdi, et al. "Current status and future prospects for esophageal cancer." Cancers 15.3 (2023): 765.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
